Kinnate Biopharma Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
17
- Latest Deal Type
-
M&A
Kinnate Biopharma General Information
Description
Developer of small-molecule kinase inhibitors intended to treat genomically defined cancers. The company operates as a clinical-stage precision oncology company focused on the discovery and design of therapies for difficult-to-treat, genomically defined cancers.
Contact Information
Website
www.kinnate.comCorporate Office
- 11975 El Camino Real
- Suite 101
- San Diego, CA 92130
- United States
Corporate Office
- 11975 El Camino Real
- Suite 101
- San Diego, CA 92130
- United States
Kinnate Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 14-Apr-2025 | Completed | Generating Revenue | |||
| 6. Merger/Acquisition | 03-Apr-2024 | Completed | Generating Revenue | |||
| 5. IPO | 03-Dec-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC | Completed | Clinical Trials - Phase 1 | ||||
| 3. Later Stage VC (Series C) | 26-Aug-2020 | Completed | Startup | |||
| 2. Early Stage VC (Series B) | 12-Dec-2019 | $74.5M | $96.5M | Completed | Startup | |
| 1. Early Stage VC (Series A) | 01-Apr-2018 | $22M | $22M | Completed | Startup |
Kinnate Biopharma Comparisons
Industry
Financing
Details
Kinnate Biopharma Competitors (29)
One of Kinnate Biopharma’s 29 competitors is Erasca, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Erasca | Formerly VC-backed | San Diego, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Bolt Biotherapeutics | Formerly VC-backed | Redwood City, CA | ||||
| Accent Therapeutics | Venture Capital-Backed | Lexington, MA | ||||
| MaveriX Oncology | Venture Capital-Backed | Palo Alto, CA |
Kinnate Biopharma Patents
Kinnate Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025054260-A1 | Inhibitors of mek kinase | Inactive | 07-Sep-2023 | ||
| WO-2025024707-A1 | Inhibitors of cdk2/4/6 kinase | Inactive | 26-Jul-2023 | ||
| WO-2025024726-A1 | Inhibitors of cyclin-dependent kinase | Inactive | 26-Jul-2023 | ||
| WO-2025024665-A1 | Treatment of cancer with a cdk inhibitor | Inactive | 26-Jul-2023 | ||
| WO-2024259060-A1 | Inhibitors of met kinase | Inactive | 16-Jun-2023 | C07D471/04 |
Kinnate Biopharma Signals
Kinnate Biopharma Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Boxer Capital | Corporate Venture Capital | Minority | ||
| Citadel Enterprise Americas | Hedge Fund | Minority | ||
| Eshelman Ventures | Venture Capital | Minority | ||
| Fidelity Management & Research Company | Asset Manager | Minority | ||
| Foresite Capital | Growth/Expansion | Minority |
Kinnate Biopharma Investments & Acquisitions (3)
Kinnate Biopharma’s most recent deal was a Merger/Acquisition with Kinnjiu Biopharma for . The deal was made on 17-Feb-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Kinnjiu Biopharma | 17-Feb-2023 | Merger/Acquisition | Drug Discovery | ||
| Kinnjiu Biopharma | 13-May-2021 | Early Stage VC | Drug Discovery | ||
| Kinnjiu Biopharma | 13-May-2021 | Joint Venture | Drug Discovery |
Kinnate Biopharma ESG
Risk Overview
Risk Rating
Updated December, 31, 2022
32.08 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,942
Rank
Percentile
Pharmaceuticals
Industry
of 914
Rank
Percentile
Pharmaceuticals
Subindustry
of 436
Rank
Percentile
Kinnate Biopharma FAQs
-
When was Kinnate Biopharma founded?
Kinnate Biopharma was founded in 2018.
-
Where is Kinnate Biopharma headquartered?
Kinnate Biopharma is headquartered in San Diego, CA.
-
What is the size of Kinnate Biopharma?
Kinnate Biopharma has 17 total employees.
-
What industry is Kinnate Biopharma in?
Kinnate Biopharma’s primary industry is Drug Discovery.
-
Is Kinnate Biopharma a private or public company?
Kinnate Biopharma is a Private company.
-
What is Kinnate Biopharma’s current revenue?
The current revenue for Kinnate Biopharma is .
-
How much funding has Kinnate Biopharma raised over time?
Kinnate Biopharma has raised $434M.
-
Who are Kinnate Biopharma’s investors?
Boxer Capital, Citadel Enterprise Americas, Eshelman Ventures, Fidelity Management & Research Company, and Foresite Capital are 5 of 16 investors who have invested in Kinnate Biopharma.
-
Who are Kinnate Biopharma’s competitors?
Erasca, Kite Pharma, Bolt Biotherapeutics, Accent Therapeutics, and MaveriX Oncology are some of the 29 competitors of Kinnate Biopharma.
-
When was Kinnate Biopharma acquired?
Kinnate Biopharma was acquired on 14-Apr-2025.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process